摘要
目的探讨洛铂联合表柔比星、丝裂霉素在肝癌介入治疗中的应用效果及安全性。方法随机选取2015年5月～2017年5月宁波大学医学院附属鄞州医院收治的42例肝癌患者作为研究对象，并随机分为观察组和对照组，观察组给予洛铂联合表柔比星、丝裂霉素介入治疗，对照组给予奥沙利铂联合表柔比星、丝裂霉素介入治疗。结果2组的治疗效果相当，观察组的胃肠道反应、神经毒性、肝肾毒性等并发症发生率低于对照组，但血液毒性高于对照组，差异具有统计学意义（P＜0.05）。结论对肝癌患者实施洛铂联合表柔比星、丝裂霉素介入治疗的效果较好，不良反应发生率更低。
Objective To evaluate the efficacy and safety of pirarubicin combined with epirubicin and mitomycin in interventional treatment of hepatocellular carcinoma.Methods Randomly selected42patients admitted to the hospital as the research object,and randomly divided into observation group and control group,the observation group was given lobaplatin combined with epirubicin and mitomycin interventional therapy,the control group was given oxaliplatin combined with epirubicin and mitomycin interventional therapy.Results Two groups of treatment effect is equivalent,the observation group of gastrointestinal reaction,neurotoxicity,liver and kidney toxicity and other complications rate is lower than the control group,but the blood toxicity is higher than the control group,the difference is significant(P<0.05).Conclusion The efficacy of interventional therapy with platinum and epirubicin combined with mitomycin in patients with liver cancer is better,and the incidence of adverse reactions is lower,which has higher clinical safety.
作者
陈磊
马霁波
蒋存兵
张建雷
许文翼
陈明良
李定耀
CHEN Lei;MA Ji-bo;JIANG Cun-bing;ZHANG Jian-lei;XU Wen-yi;CHEN Ming-liang;LI Ding-yao(Department of Hepatobiliary Surgery, YinZhou Hospital Affiliated to Medical School of NingBo University, Ningbo 315040,China;YinZhou Hospital Affiliated to Medical School of NingBo University, Department of Intervention Therapy,Ningbo 315040, China)
出处
《中国生化药物杂志》
CAS
2017年第12期192-193,共2页
Chinese Journal of Biochemical Pharmaceutics
关键词
洛铂
表柔比星
丝裂霉素
肝癌介入治疗
Lobaplatin for injeetion
epirubicin
mitomycin
interventional therapy for hepatocellular carcinoma
